Synapse Open Synapse
Biology

FDA Delays PDUFA Action on Agios’ Mitapivat sNDA for SCD

GEN · · 4 min read

The FDA has delayed a decision on Agios Pharmaceuticals’ supplemental New Drug Application (sNDA) seeking additional approval for mitapivat in sickle cell disease (SCD) until next year.

Latest from GEN